Your browser doesn't support javascript.
loading
The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis.
Xavier, Mariana S; Araujo-Pereira, Mariana; de Oliveira, Quezia M; Sant'Anna, Flavia M; Ridolfi, Felipe M; de Andrade, Alice M S; Figueiredo, Marina C; Sterling, Timothy R; Gordhan, Bhavna G; Kana, Bavesh D; Andrade, Bruno B; Rolla, Valeria C; Gomes-Silva, Adriano.
Afiliação
  • Xavier MS; Pós-graduação em Pesquisa Clínica em Doenças Infecciosas, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
  • Araujo-Pereira M; Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, FIOCRUZ, Bahia, Brazil.
  • de Oliveira QM; Curso de Medicina, Faculdade ZARNS, Bahia, Brazil.
  • Sant'Anna FM; Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Bahia, Brazil.
  • Ridolfi FM; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
  • de Andrade AMS; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
  • Figueiredo MC; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
  • Sterling TR; Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Bahia, Brazil.
  • Gordhan BG; Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, United States.
  • Kana BD; Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, United States.
  • Andrade BB; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.
  • Rolla VC; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.
  • Gomes-Silva A; Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, FIOCRUZ, Bahia, Brazil.
Front Immunol ; 15: 1357360, 2024.
Article em En | MEDLINE | ID: mdl-38994357
ABSTRACT

Background:

The impact of previous SARS-CoV-2 infection on the systemic immune response during tuberculosis (TB) disease has not been explored.

Methods:

An observational, cross-sectional cohort was established to evaluate the systemic immune response in persons with pulmonary tuberculosis with or without previous SARS-CoV-2 infection. Those participants were recruited in an outpatient referral clinic in Rio de Janeiro, Brazil. TB was defined as a positive Xpert-MTB/RIF Ultra and/or a positive culture of Mycobacterium tuberculosis from sputum. Stored plasma was used to perform specific serology to identify previous SARS-CoV-2 infection (TB/Prex-SCoV-2 group) and confirm the non- infection of the tuberculosis group (TB group). Plasmatic cytokine/chemokine/growth factor profiling was performed using Luminex technology. Tuberculosis severity was assessed by clinical and laboratory parameters. Participants from TB group (4.55%) and TB/Prex-SCoV-2 (0.00%) received the complete COVID-19 vaccination.

Results:

Among 35 participants with pulmonary TB, 22 were classified as TB/Prex-SCoV-2. The parameters associated with TB severity, together with hematologic and biochemical data were similar between the TB and TB/Prex-SCoV-2 groups. Among the signs and symptoms, fever and dyspnea were significantly more frequent in the TB group than the TB/Prex-SCoV-2 group (p < 0,05). A signature based on lower amount of plasma EGF, G-CSF, GM-CSF, IFN-α2, IL-12(p70), IL-13, IL-15, IL-17, IL-1ß, IL-5, IL-7, and TNF-ß was observed in the TB/Prex-SCoV-2 group. In contrast, MIP-1ß was significantly higher in the TB/Prex-SCoV-2 group than the TB group.

Conclusion:

TB patients previously infected with SARS-CoV-2 had an immunomodulation that was associated with lower plasma concentrations of soluble factors associated with systemic inflammation. This signature was associated with a lower frequency of symptoms such as fever and dyspnea but did not reflect significant differences in TB severity parameters observed at baseline.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Citocinas / SARS-CoV-2 / COVID-19 Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Front Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Citocinas / SARS-CoV-2 / COVID-19 Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Front Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça